{'fraction_non_alphanumeric': 0.029315960912052116, 'fraction_numerical': 0.006514657980456026, 'mean_word_length': 4.7625, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time.

AIM
We investigated the effect of cell seeding dose and incubation time on tissue-engineered vascular graft (TEVG) patency.


MATERIALS & METHODS
Various doses of bone marrow-derived mononuclear cells (BM-MNCs) were seeded onto TEVGs, incubated for 0 or 12 h, and implanted in C57BL/6 mice. Different doses of human BM-MNCs were seeded onto TEVGs and measured for cell attachment.


RESULTS
The incubation time showed no significant effect on TEVG patency. However, TEVG patency was significantly increased in a dose-dependent manner. In the human graft, more bone marrow used for seeding resulted in increased cell attachment in a dose-dependent manner.


CONCLUSION
Increasing the BM-MNC dose and reducing incubation time is a viable strategy for improving the performance and utility of the graft.